Advancing Antibody Discovery for GPCR Targets Through In Vivo Validation of an Agonistic Antibody

• Describing the discovery strategy used to generate an agonistic antibody, including target selection and screening approaches
• Demonstrating in vivo validation of the agonistic antibody and the pharmacological activity observed across relevant models
• Detailing key translational learnings from the program and how these insights inform broader GPCR-directed antibody discovery efforts

Speakers:

Thomas Fontaine

Associate Scientist

Confo Therapeutics